Chemically modified peptides and proteins - Critical considerations for oral delivery

Tissue Barriers

Volumn 4, Issue 2, 2016, Pages

  Buckley, Stephen T ^a   Hubálek, František ^a   Rahbek, Ulrik Lytt ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Absorption; Bioconjugate; Cell penetrating peptide; Chemical modification; Ligand attachment; Lipidisation; Oral delivery; Peptide; Protein

Indexed keywords

CELL PENETRATING PEPTIDE; CYANOCOBALAMIN; GLYCOSAMINOGLYCAN;

CHEMICAL MODIFICATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; HUMAN; HYDROPHILICITY; IMMUNOGENICITY; INTESTINE CELL; INTESTINE EPITHELIUM CELL; PHYSICAL CHEMISTRY; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; TRANSCYTOSIS; ANIMAL; CHEMISTRY; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CELL-PENETRATING PEPTIDES; HUMANS; INTESTINAL ABSORPTION;

EID: 84996595366     PISSN: 21688362     EISSN: 21688370     Source Type: Journal    
DOI: 10.1080/21688370.2016.1156805     Document Type: Review

References (53)

1. Y.N.1.Abdiche, Y.A.Yeung, J.Chaparro-Riggers, I.Barman, P.Strop, S.M.Chin, A.Pham, G.Bolton, D.McDonough, K.Lindquist, The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 2015; 7(2):331–43; PMID:25658443; http://dx.doi.org/10.1080/19420862.2015.1008353
2. T.A.Al-Hilal, F.Alam, Y.Byun. Oral drug delivery systems using chemical conjugates or physical complexes. Adv Drug Delivery Rev 2013 65:845–864; PMID:23220326; http://dx.doi.org/10.1016/j.addr.2012.11.002
3. T.A.Al-Hilal, S.W.Chung, F.Alam, J.Park, K.E.Lee, H.Jeon, K.Kim, I.C.Kwon, I.S.Kim, S.Y.Kim, Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci Rep 2014; 4:4163; PMID:24566561; http://dx.doi.org/10.1038/srep04163
4. J.Alsenz, G.J.Russell-Jones, S.Westwood, B.Levet-Trafit, P.C.de Smidt. Oral absorption of peptides through the cobalamin (vitamin B12) pathway in the rat intestine. Pharm Res 2000 Jul; 17(7):825–32; PMID:10990201; http://dx.doi.org/10.1023/A:1007556108673
5. N.Amet, W.Wang, W.C.Shen. Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release 2010 141(2):177–82; PMID:19761807; http://dx.doi.org/10.1016/j.jconrel.2009.09.007
6. P.Bailon, C.Y.Won. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009 Jan; 6(1):1–16; PMID:19236204; http://dx.doi.org/10.1517/17425240802650568
7. A.Balakrishnan, J.E.Polli. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 2006 May—Jun; 3(3): 223–230; PMID:16749855; http://dx.doi.org/10.1021/mp060022d
8. R.Brock The uptake of arginine-rich cell-penetrating peptides: putting the puzzle together. Bioconjug Chem 2014; 25(5):863–8; PMID:24679171; http://dx.doi.org/10.1021/bc500017t
9. T.Buclin, M.Cosma Rochat, P.Burckhardt, M.Azria, M.Attinger. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002 Aug; 17(8):1478–85; PMID:12162502; http://dx.doi.org/10.1359/jbmr.2002.17.8.1478
10. K.B.Chalasani, G.J.Russell-Jones, A.K.Jain, P.V.Diwan, S.K.Jain. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007 Sep 26; 122(2):141–50; PMID:17707540; http://dx.doi.org/10.1016/j.jconrel.2007.05.019
11. D.J.Chinnapen, W.T.Hsieh, Y.M.te Welscher, D.E.Saslowsky, L.Kaoutzani, E.Brandsma, L.D'Auria, H.Park, J.S.Wagner, K.R.Drake, Lipid sorting by ceramide structure from plasma membrane to ER for the cholera toxin receptor ganglioside GM1. Dev Cell 2012 Sep 11; 23(3):573–86; PMID:22975326; http://dx.doi.org/10.1016/j.devcel.2012.08.002
12. S.Clement, P.Dandona, J.G.Still, G.Kosutic. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 2004 Jan; 53(1):54–8; PMID:14681842; http://dx.doi.org/10.1016/j.metabol.2003.07.021
13. X.Du, K.Beloussow, W.C.Shen. Bowman-Birk protease inhibitor and its palmitic acid conjugate prevent 7,12-dimethylbenz[a]anthracene-induced transformation in cultured mouse mammary glands. Cancer Lett 2001 Mar 26; 164(2):135–41; PMID:11179827; http://dx.doi.org/10.1016/S0304-3835(01)00381-0
14. H.M.Ekrami, A.R.Kennedy, W.C.Shen. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett 1995 Sep 11; 371(3):283–6; PMID:7556611; http://dx.doi.org/10.1016/0014-5793(95)00910-2
15. M.Estudante, J.G.Morais, G.Soveral, L.Z.Benet. Intestinal drug transporters: an overview. Adv Drug Deliv Rev 2013 Oct; 65(10):1340–56; PMID:23041352; http://dx.doi.org/10.1016/j.addr.2012.09.042
16. S.N.Fedosov, C.B.Grissom, N.U.Fedosova, S.K.Moestrup, E.Nexø, T.E.Petersen. Application of a fluorescent cobalamin analogue for analysis of the binding kinetics. A study employing recombinant human transcobalamin and intrinsic factor. FEBS J 2006 Oct; 273(20):4742–53; PMID:16984395; http://dx.doi.org/10.1111/j.1742-4658.2006.05478.x
17. C.Foged, H.M.Nielsen. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 2008; 5(1):105–17; PMID:18095931; http://dx.doi.org/10.1517/17425247.5.1.105
18. H.He, J.Sheng, A.E.David, Y.M.Kwon, J.Zhang, Y.Huang, J.Wang, V.C.Yang. The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials 2013 Oct; 34(31):7733–43; PMID:23863452; http://dx.doi.org/10.1016/j.biomaterials.2013.06.047
19. P.Hindlet, C.Barraud, L.Boschat, R.Farinotti, A.Bado, M.Buyse. Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter. Mol Pharmacol 2012 Mar; 81(3):319–27; PMID:22108913; http://dx.doi.org/10.1124/mol.111.073874
20. P.J.Hornby, P.R.Cooper, C.Kliwinski, E.Ragwan, J.R.Mabus, B.Harman, S.Thompson, A.L.Kauffman, Z.Yan, S.H.Tam, Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res 2014 Apr; 31(4):908–22; PMID:24072267; http://dx.doi.org/10.1007/s11095-013-1212-3
21. S.A.Ingersoll, S.Ayyadurai, M.A.Charania, H.Laroui, Y.Yan, D.Merlin. The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2012 Mar 1; 302(5):G484–92; PMID:22194420; http://dx.doi.org/10.1152/ajpgi.00477.2011
22. N.Kamei, Y.Onuki, K.Takayama, M.Takeda-Morishita. Mechanistic study of the uptake/permeation of cell-penetrating peptides across a caco-2 monolayer and their stimulatory effect on epithelial insulin transport. J Pharm Sci 2013; 102(11):3998–4008; PMID:23963728; http://dx.doi.org/10.1002/jps.23708
23. A.J.Keefe, S.Jiang. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat Chem 2011 Dec 11; 4(1):59–63; PMID:22169873; http://dx.doi.org/10.1038/nchem.1213
24. A.Khedkar, H.Iyer, A.Anand, M.Verma, S.Krishnamurthy, S.Savale, A.Atignal. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab 2010 Aug; 12(8):659–64; PMID:20590742; http://dx.doi.org/10.1111/j.1463-1326.2010.01213.x
25. J.H.Kim, C.L.Bronson, W.L.Hayton, M.D.Radmacher, D.C.Roopenian, J.M.Robinson, C.L.Anderson. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2006 Feb; 290(2):G352–60; PMID:16210471; http://dx.doi.org/10.1152/ajpgi.00286.2005
26. M.Kristensen, A.M.de Groot, J.Berthelsen, H.Franzyk, A.Sijts, H.M.Nielsen. Conjugation of cell-penetrating peptides to parathyroid hormone affects its structure, potency, and transepithelial permeation. Bioconjug Chem 2015; 26(3):477–88; PMID:25611217; http://dx.doi.org/10.1021/bc5005763
27. X.Li, M.Yu, W.Fan, Y.Gan, L.Hovgaard, M.Yang. Orally active-targeted drug delivery systems for proteins and peptides. Expert Opin Drug Deliv 2014; 11(9):1435–1447; PMID:24962803; http://dx.doi.org/10.1517/17425247.2014.924500
28. S.C.Low, S.L.Nunes, A.J.Bitonti, J.A.Dumont. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005 Jul; V20(7):1805–13; PMID:15817590; http://dx.doi.org/10.1093/humrep/deh896
29. K.Ma, Y.Hu, D.E.Smith. Influence of fed-fasted state on intestinal PEPT1 expression and in vivo pharmacokinetics of glycylsarcosine in wild-type and Pept1 knockout mice. Pharm Res 2012 Feb; 29(2):535–45; PMID:21904935; http://dx.doi.org/10.1007/s11095-011-0580-9
30. K.Marciniuk, B.2.Trost, S.Napper. EpIC: a rational pipeline for epitope immunogenicity characterization. Bioinformatics 2015 Jul 15; 31(14):2388–90; PMID:25750418; http://dx.doi.org/10.1093/bioinformatics/btv136
31. E.Neimark, F.Chen, X.Li, B.L.Shneider. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 2004; 40(1):149–56; PMID:15239098; http://dx.doi.org/10.1002/hep.20295
32. G.E.Peterson, R.D.Pollom. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract Suppl 2010 Oct;(167):35–43; PMID:20949699; http://dx.doi.org/10.1111/j.1742-1241.2010.02498.x
33. E.M.Pridgen, F.Alexis, O.C.Farokhzad. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv 2015; 12(9):1459–73; PMID:25813361; http://dx.doi.org/10.1517/17425247.2015.1018175
34. E.M.Pridgen, F.Alexis, T.T.Kuo, E.Levy-Nissenbaum, R.Karnik, R.S.Blumberg, R.Langer, O.C.Farokhzad. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 2013 Nov 27; 5(213):213ra167; PMID:24285486; http://dx.doi.org/10.1126/scitranslmed.3007049
35. G.J.Russell-Jones, S.W.Westwood, P.G.Farnworth, J.K.Findlay, H.G.Burger. Synthesis of LHRH antagonists suitable for oral administration via the vitamin B12 uptake system. Bioconjug Chem 1995 Jan-Feb; 6(1):34–42; PMID:7711102; http://dx.doi.org/10.1021/bc00031a600
36. G.J.Russell-Jones, S.W.Westwood, A.D.Habberfield. Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin. Bioconjug Chem 1995 Jul-Aug; 6(4):459–65; PMID:7578366; http://dx.doi.org/10.1021/bc00034a016
37. G.Russell-Jones. Intestinal receptor targeting for peptide delivery: an expert’s personal perspective on reasons for failure and new opportunities. Therapeutic Delivery 2011 2(12):1575–1593; PMID:22833983; http://dx.doi.org/10.4155/tde.11.129
38. A.L.Smart, S.Gaisford, A.W.Basit. Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 2014; 11(8):1323–35; PMID:24816134; http://dx.doi.org/10.1517/17425247.2014.917077
39. J.T.Sockolosky, M.R.Tiffany, F.C.Szoka. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A 2012 109(40):16095–100; PMID:22991460; http://dx.doi.org/10.1073/pnas.1208857109
40. T.Szekeres, J.Sedlak, L.Novotny. Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells. Curr Med Chem 2002; 9(7):759–64; PMID:11966439; http://dx.doi.org/10.2174/0929867024606911
41. Y.Takechi, Y.Yanagisawa, K.Nishitsuji, K.Uchimura, T.Kawakami, K.Kawakami, K.Okuhira, H.Saito. Arginine-glycosaminoglycan interaction regulates penetration efficiency of arginine-rich cell-penetrating peptides in biological membrane. Biophys J 2015; 108(2);82a; http://dx.doi.org/10.1016/j.bpj.2014.11.482
42. J.Temsamani, P.Vidal. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004 ;9(23):1012–9; PMID:15574317; http://dx.doi.org/10.1016/S1359-6446(04)03279-9
43. T.Ying, W.Chen, Y.Feng, Y.Wang, R.Gong, D.S.Dimitrov. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013 Aug 30; 288(35):25154–64; PMID:23867459; http://dx.doi.org/10.1074/jbc.M113.484154
44. A.van Agthoven, C.Goridis, P.Naquet, A.Pierres, M.Pierres. Structural characteristics of the mouse transferrin receptor. Eur J Biochem 1984; 140(2):433–40; PMID:6325190; http://dx.doi.org/10.1111/j.1432-1033.1984.tb08121.x
45. F.M.Veronese, A.Mero. The impact of PEGylation on biological therapies. BioDrugs 2008; 22(5):315–29; PMID:18778113; http://dx.doi.org/10.2165/00063030-200822050-00004
46. K.M.Wagstaff, D.A.Jans. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem 2006; 13(12):1371–87; PMID:16719783; http://dx.doi.org/10.2174/092986706776872871
47. J.Wang, D.Wu, W.C.Shen. Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm Res 2002 May; 19(5):609–14; PMID:12069162; http://dx.doi.org/10.1023/A:1015397811161
48. J.Wang, D.Chow, H.Heiati, W.C.Shen. Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release 2003 Mar 26; 88(3):369–80; PMID:12644363; http://dx.doi.org/10.1016/S0168-3659(03)00008-7
49. Y.M.Welscher, D.J.Chinnapen, L.Kaoutzani, R.J.Mrsny, W.I.Lencer. Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP-1. J Control Release 2014 Feb 10; 175:72–8; PMID:24370893; http://dx.doi.org/10.1016/j.jconrel.2013.12.013
50. J.T.White, M.Crossman, K.Richter, M.Berman, J.Goyal, M.Subramanyam. Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1a. Bioanalysis 2015 Nov; 7(21):2801–11; PMID:26541956; http://dx.doi.org/10.4155/bio.15.197
51. A.Widera, F.Norouziyan, W.C.Shen. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 2003 Nov 14; 55(11):1439–66; PMID:14597140; http://dx.doi.org/10.1016/j.addr.2003.07.004
52. Y.J.Yu, Y.Zhang, M.Kenrick, K.Hoyte, W.Luk, Y.Lu, J.Atwal, J.M.Elliott, S.Prabhu, R.J.Watts, Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3(84):84ra44; PMID:21613623; http://dx.doi.org/10.1126/scitranslmed.3002230
53. H.Zhao, D.Verma, W.Li, Y.Choi, C.Ndong, S.N.Fiering, C.Bailey-Kellogg, K.E.Griswold. Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo. Chem Biol 2015 May 21; 22(5):629–39; PMID:26000749; http://dx.doi.org/10.1016/j.chembiol.2015.04.017